Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Impact · against what's priced in

Agenus shares are likely to react positively as the company provides updated clinical evidence of durable survival for the botensilimab and balstilimab combination. The presentation of this data in an oral session at ESMO 2025 increases visibility and supports the potential for regulatory success in late-stage refractory solid tumors.

AGEN+0.70

No priced-in read yet